Aytu Biopharma (AYTU) Total Debt (2011 - 2026)

Aytu Biopharma (AYTU) has 15 years of Total Debt data on file, last reported at $11.4 million in Q1 2026.

• On a quarterly basis, Total Debt changed 0.12% year-over-year to $11.4 million in Q1 2026; TTM through Mar 2026 was $11.4 million, a 0.12% change from a year earlier, with the FY2025 full-year figure at $20.0 million, up 50.38% from the prior year.
• Total Debt for Q1 2026 stood at $11.4 million, down from $19.1 million in the prior quarter.
• Over the last five years, Total Debt for AYTU reached as high as $23.1 million in Q3 2022 and fell as low as $1.6 million in Q1 2024.
• Historically, Total Debt has averaged $14.6 million across 5 years, with a median of $14.7 million in 2023.
• Across the five-year window, Total Debt jumped 995.36% in 2022 and slumped 89.24% in 2024, its largest moves.
• Year by year, Total Debt stood at $14.6 million in 2022, then climbed by 9.44% to $16.0 million in 2023, then fell by 26.02% to $11.8 million in 2024, then soared by 61.09% to $19.1 million in 2025, then sank by 40.2% to $11.4 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $11.4 million in Q1 2026, $19.1 million in Q4 2025, and $12.3 million in Q3 2025.